The clinical investigator

, Volume 72, Issue 12, pp 1015–1019 | Cite as

Development of resistance byEnterobacter cloacae during therapy of pulmonary infections in intensive care patients

  • R. Füssle
  • J. Biscoping
  • R. Behr
  • A. Sziegoleit
Original Articles


The emergence of resistance during therapy and the efficacy of different antibiotic therapy regimens were studied in 38 intensive care patients suffering from pulmonary infections caused byEnterobacter cloacae. Every three days a fresh isolate was obtained from each patient and tested in vitro for susceptibility to 16 antibiotics by determination of the minimal inhibitory concentrations. During therapy with cefotaxime and tobramycin theE. cloacae strains from 47% of the patients became resistant to cefotaxime within 6 days. In all cases resistance encompassed all other broad-spectrum penicillins and cephalosporins tested, as well as aztreonam. Development of resistance regularly led to persistence of bacteria. Resistance to tobramycin, ciprofloxacin or imipenem was not observed. Treatment of 25 patients with persistingE. cloacae infections was successful in 17 out of 18 patients treated with imipenem and in 6 out of 7 patients receiving ciprofloxacin.

Key words

Enterobacter Infections Resistance Antibiotics 



Minimal inhibitory concentration


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chastre J, Viau F, Brun P, Pierre J, Dauge MC, Bochama A, Akesbi A, Gilbert C (1984) Prospective evaluation of the protected specimen brush for the diagnosis of pulmonary infections in ventilated patients. Am Rev Resp Dis 130:924–929Google Scholar
  2. 2.
    Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VV (1991) Enterobacter bacteremia: clinical features and emergence of resistance during therapy. Ann Intern Med 115:585–590Google Scholar
  3. 3.
    Conus P, Francioli P (1992) Relationship between Ceftriaxone use and resistance ofEnterobacter species. J Clin Pharm Ther 17:303–305Google Scholar
  4. 4.
    Farmer JJ, Kelly MT (1991) Enterobacteriaceae. In: Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ (eds) Manual of clinical microbiology. American Society for Microbiology, Washington DC, pp 360–383Google Scholar
  5. 5.
    Flynn DM, Weinstein RA, Nathan C, Gaston A, Kabins SA (1987) Patients endogenous flora as the source of “nosocomial” Enterobacter in cardiac surgery. J Infect Dis 156:363–368Google Scholar
  6. 6.
    Füssle R, Biscoping J, Zeiler D, Michaelis G, Sziegoleit A (1991) Microbiologic monitoring of ventilated patients. A concept for diagnosis and therapy of pulmonary infections. Anaesthesist 40:491–496Google Scholar
  7. 7.
    Jones RN (1992) The current and future impact of antimicrobial resistance among nosocomial pathogens. Diagn Microbiol Infect Dis 15:3–10Google Scholar
  8. 8.
    Livermore DM (1987) Clinical significance of beta lactamase induction and stable derepression in gram-negative rods. Eur J Clin Microbiol 6:439–445Google Scholar
  9. 9.
    Milatovic D, Braveny I (1987) Development of resistance during antibiotic therapy. Eur J Clin Microbiol Infect Dis 6:234–244Google Scholar
  10. 10.
    Murray BE (1991) New aspects of antimicrobial resistance and the resulting therapeutic dilemmas. J Infect Dis 163:1185–1194Google Scholar
  11. 11.
    Murray PR, Granich GG, Krogstad DJ, Niles AC (1983) In vivo selection of resistance to multiple cephalosporins byEnterobacter cloacae. J Infect Dis 147:590–595Google Scholar
  12. 12.
    National Committee for Clinical Laboratory Standards (1990) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A2. NCCLS, Villanova, PaGoogle Scholar
  13. 13.
    Olson B, Weinstein RA, Nathan C, Kabins SA (1983) Broadspectrum β-lactam resistance inEnterobacter: emergence during treatment and mechanisms of resistance. J Antimicrob Chemother 11:299–310Google Scholar
  14. 14.
    Platt R, Ehrlich S, Afarian J, O Brien TF, Pennington JE, Kass EH (1981) Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy. Antimicrob Agents Chemother 20:351–355Google Scholar
  15. 15.
    Richmond MH, Sykes RB (1973) The β-lactamases of gram-negative bacteria and their possible physiological role. Adv Microbiol Physiol 9:31–88Google Scholar
  16. 16.
    Sanders CC (1984) Inducible β-lactamases and non-hydrolytic resistance mechanisms. J Antimicrob Chemother 13:1–3Google Scholar
  17. 17.
    Sanders CC, Sanders WE (1983) Emergence of resistance during therapy with the newer beta-lactam antibiotics, role of inducible β-lactamases and implications for the future. Rev Infect Dis 5:639–641Google Scholar
  18. 18.
    Sanders CC, Sanders WE (1985) Microbial resistance to newer generation β-lactam antibiotics: clinical and laboratory implications. J Infect Dis 151:399–406Google Scholar
  19. 19.
    Sanders CC, Sanders WE (1986) Type I β-lactamases of gram-negative bacteria: interactions with β-lactam antibiotics. J Infect Dis 154:792–800Google Scholar
  20. 20.
    Seeberg AH, Tolxdorff-Neutzling RM, Wiedemann B (1983) Chromosomal β-lactamases ofEnterobacter cloacae are responsible for resistance to third generation cephalo- sporines. Antimicrob Agents Chemother 23:918–925Google Scholar
  21. 21.
    Wiedemann B (1986) Genetic and biochemical basis of resistance ofEnterobacter cloacae to β-lactam antibiotics. J Antimicrob Chemother 18 [Suppl B]:31–38Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • R. Füssle
    • 1
  • J. Biscoping
    • 2
  • R. Behr
    • 3
  • A. Sziegoleit
    • 1
  1. 1.Institut für Medizinische MikrobiologieUniversität GiessenGiessenGermany
  2. 2.Abteilung für Anaesthesiologie und Operative IntensivmedizinGiessenGermany
  3. 3.Neurochirurgische KlinikUniversität GiessenGiessenGermany

Personalised recommendations